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ABSTRACT. The forthcoming DSM edition (DSM 5) will be published in May, 2013.
Drafts that have been made available up to the present have launched several controversies.
One of them is a possible diagnosis inflation that would generate an epidemic of false
positive cases. The case of the proposed «Attenuated Psychotic Syndrome» is an
important example, but others like the «Mild Neurocognitive Disorder» or the «Binge
Eating Disorder» add to the list of controversial new proposals. Moreover, some
methodological aspects of the whole procedure, including the imposition of a nondisclosure
agreement, the lack of transparency and possible conflicts of interests have also been
condemned. Historical developments of the DSM’s evolution are reviewed: DSM-III
and its «diagnostic reliability revolution», DSM-IV’s validity problems and the doubts
raised by DSM-V’s expected «dimensional paradigm» shift. Finally, the prospect of
neuroscience research as a possible way to overcome the present nosological problems
is analyzed.
KEYWORDS. DSM 5. DSM III. DSM IV. Dimensional paradigm. Neurosciences.
Theoretical study.
RESUMEN. La próxima edición del DSM (DSM 5) aparecerá en Mayo de 2013. Los
borradores publicados ya han generado diversas polémicas. Se ha criticado la posible
inflación diagnóstica con una previsible epidemia de falsos positivos en nuevos diag-
nósticos como el «síndrome psicótico atenuado». La propuesta de otros nuevos diag-
nósticos como el «trastorno cognitivo leve», el «trastorno por atracones» o las «adicciones
conductuales», entre otros, se suman a esta polémica. También se han criticado ciertos
aspectos metodológicos del proceso, como la exigencia de confidencialidad y la falta de
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transparencia y los conflictos de intereses. El artículo repasa los antecedentes históricos
del proceso DSM, con la revolución en la fiabilidad diagnóstica del DSM-III, los
problemas de validez del DSM IV y las dudas que genera el DSM 5 en el supuesto
cambio de «paradigma dimensional». Asimismo, se apunta a posibles vías futuras de
solución, más allá del DSM 5, en el avance de las ciencias básicas del cerebro y de la
conducta.
PALABRAS CLAVE. DSM 5. DSM III. DSM IV. Paradigma dimensional. Neurociencias.
Estudio teórico.
DSM-III: Grandpa was great
Let’s go back some 40 years, to the early 70’s. The USA-UK Cross National Project
demonstrated in 1972 (Cooper, Kendell, and Gurland, 1972) the extreme weakness and
low reliability of psychiatric diagnoses, especially in the field of psychosis. The times
were ready for a methodological revolution in psychopathology and psychiatry and
soon major advances in psychiatric diagnoses appeared. The pioneering work of the
Saint Louis group, conducted by Robins and Guze, was important because its classification
(Feighner et al., 1972) was adopted by the Research Diagnostic Criteria, which was then
adopted by DSM-III. Hence this paper was a precursor to modern psychiatric classification.
DSM-III (American Pyschiatric Association, 1980) was a major scientific achievement.
By creating a system of explicit, operationalized diagnostic criteria, DSM-III faced up
to the pressing problem of interrater reliability in psychiatric diagnosis. It became
necessary in the 1970s to facilitate diagnostic agreement among clinicians, scientists,
and regulatory authorities given the need to match patients with newly emerging
pharmacologic treatments and the associated need to conduct replicable clinical trials
so that additional treatments could be approved. Researchers around the world could
since speak a common diagnostic language. While it is true that no system based
entirely on clinical description can match the levels of diagnostic agreement made
possible by objective medical tests, there were no good alternatives for psychiatry when
DSM-III was published in 1980. Indeed, even today objective tests and biomarkers for
mental disorders remain research goals rather than clinical tools (Bernstein, 2011).
Should DSM 5 represent a step forward regarding reliability power? Or rather
should our expectations of DSM 5 diagnoses be viewed in the context of what is known
about the reliability and validity of diagnoses throughout medicine and not be set
unrealistically high, exceeding the standards that pertain to the rest of medicine? Kraemer,
Kupfer, Clarke, Narrow, and Regier (2012, p. 13 ) shed some light on this issue: «While
one occasionally sees (in medical reliability studies) interrater kappa values between .60
and .80, the more common range is between .40 and .60. From these results, to see a
kappa value for a DSM 5 diagnosis above .80 would be almost miraculous; to see k
between .60 and .80 would be cause for celebration. A realistic goal is k between .40
and .60, while k between .20 and .40 would be acceptable. We expect that the reliability
(intraclass correlation coefficient) of DSM 5 dimensional measures will be larger, and we
will aim for between .60 and .80 and accept between .40 and .60».
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DSM-IV: Problems with dad
The big success of the DSM system has, paradoxically, given rise to a serious side
effect: reification. APA Past-President Carol A. Bernstein has written: «DSM diagnoses
have come, over the last four decades, to be treated as «real entities» in the world, that
is, they have been reified. Just as clinicians need DSM-IV diagnoses to select treatments,
to communicate with each other and with patients, and to be reimbursed, scientists must
generally use DSM-IV criteria to obtain a research grant or to have a paper accepted
by a journal. Industry must use DSM-IV criteria in the design of clinical trials if they
are to gain approval from the Food and Drug Administration for a new treatment. As
a result, clinical and translational researchers have largely based their work on DSM-
IV disorders…» (Bernstein, 2011, p. 7).
Other serious critiques to DSM-IV have pointed to: a) the exceedingly high rates
of comorbidity, especially in some areas (e.g., anxiety disorders, personality disorders);
b) changes to the previous version seem to have contributed to three false positive
«epidemics» - high rates of attention deficit hyperactivity disorder, autistic disorder, and
childhood bipolar disorders. Clearly, there were other factors that also contributed, in
particular drug companies marketing drugs for these diagnoses (Moynihan, Heath,
Henry, and Gotzsche, 2002) directed not only to doctors but also the general public
(Wykes and Callard, 2010); c) the widespread need for «not otherwise specified» (NOS)
criteria. In some areas of practice, such as eating disorders, personality disorders, or
autism spectrum disorders, NOS may be more prevalent than specific DSM-IV diagnoses.
So, while initially a great aid to the study of mental illness by ensuring the comparability
of research results, the DSM system has not yet solved the validity problem. Most DSM
diagnoses are not etiologically based entities and are not grounded on critical therapeutic
reasons. Moreover, they are neither particularly good entities (phenotypes) for research
purposes. The case of schizophrenia is the unfortunate leader in this regard.
DSM 5: Bad omen before delivery…
The draft diagnostic criteria for DSM 5 has already been released. In the DSM 5
official site we can read the revisions that include the following.
– The recommendation of new categories for learning disorders and a single
diagnostic category, «autism spectrum disorders» that will incorporate the current
diagnoses of autistic disorders, Asperger’s Syndrome, childhood disintegrative
disorder and pervasive developmental disorder (not otherwise specified). Work
group members have also recommended that the diagnostic term «mental
retardation» be changed to «intellectual disability,» bringing the DSM criteria
into alignment with terminology used by other disciplines.
– Eliminating the current categories substance abuse and dependence, replacing
them with the new category «addiction and related disorders.» This will include
substance use disorders, with each drug identified in its own category. Eliminating
the category of dependence will better differentiate between the compulsive
drug-seeking behavior of addiction and normal responses of tolerance and
withdrawal that some patients experience when using prescribed medications
that affect the central nervous system.
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– Creating a new category of «behavioral addictions,» in which gambling will be
the sole disorder. Internet addiction was considered for this category, but work
group members decided there was insufficient research data to do so, so they
recommended it be included in the manual’s appendix instead, with a goal of
encouraging additional study.
– New suicide scales for adults and adolescents to help clinicians identify those
individuals most at risk, with a goal of enhancing interventions across a broad
range of mental disorders; the scales include research-based criteria such as
impulsive behavior and heavy drinking in teens.
– Consideration of a new «risk syndromes» category, with information to help
clinicians identify earlier stages of some serious mental disorders, such as
neurocognitive disorder (dementia) and psychosis.
– A proposed new diagnostic category, temper dysregulation with dysphoria (TDD),
within the Mood Disorders section of the manual. The new criteria are based on
a decade of research on severe mood dysregulation, and may help clinicians
better differentiate children with these symptoms from those with bipolar disorder
or oppositional defiant disorder.
– New recognition of binge eating disorder and improved criteria for anorexia
nervosa and bulimia nervosa, as well as recommended changes in the definitions
of some eating disorders now described as beginning in infancy and childhood
to emphasize that they may also develop in older individuals (American Psychiatric
Association, Announces Draft Diagnostic Criteria for DSM-5 2010a). The present
proposed general revision is listed on Table 1.
TABLE 1. Proposed DSM 5 organizational structure.
- Neurodevelopmental Disorders 
- Schizophrenia Spectrum and Other Psychotic Disorders 
- Bipolar and Related Disorders 
- Depressive Disorders 
- Anxiety Disorders 
- Obsessive-Compulsive and Related Disorders 
- Trauma- and Stressor-Related Disorders 
- Dissociative Disorders 
- Somatic Symptom Disorders 
- Feeding and Eating Disorders 
- Elimination Disorders 
- Sleep-Wake Disorders 
- Sexual Dysfunctions 
- Gender Dysphoria 
- Disruptive, Impulse Control, and Conduct Disorders 
- Substance Use and Addictive Disorders 
- Neurocognitive Disorders 
- Personality Disorders 
- Paraphilias 
- Other Disorders 
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In addition to proposed changes to specific diagnostic criteria, the American
Psychiatric Association (APA) is proposing that «dimensional assessments» be added
to diagnostic evaluations of mental disorders. These would permit clinicians to evaluate
the severity of symptoms, as well as take into account «crosscutting» symptoms
(American Psychiatric Association, Announces Draft Diagnostic Criteria for DSM-5,
2010a).
The field of Personality Disorders is perhaps the best example of this aim. A hybrid
dimensional-categorical model for personality and personality disorder assessment and
diagnosis has been proposed for DSM 5 field testing. Six specific personality disorder
types (antisocial, avoidant, borderline, narcissistic, obsessive-compulsive, and, schizotypal)
are defined by criteria based on typical impairments in personality functioning and
pathological personality traits in one or more trait domains. The diagnosis of Personality
Disorder Trait Specified (PDTS) is defined by significant impairment in personality
functioning, as measured by the Levels of Personality Functioning scale, and one or
more pathological personality trait domains or trait facets. PDTS replaces Personality
Disorder Not Otherwise Specified in the proposed DSM 5 system.
The levels of personality functioning are based on the severity of disturbances in
self and interpersonal functioning. Impairments in self-functioning are reflected in
dimensions of identity and self-directedness. Interpersonal impairments consist of
impairments in the capacities for empathy and intimacy. Five broad personality trait
domains (negative affectivity, detachment, antagonism, disinhibition vs. compulsivity,
and psychoticism) are defined, as well as component trait facets (for example, impulsivity
and rigid perfectionism) (American Psychiatric Association, DSM-5 Development, 2011).
A «Guide to Implementation» is provided to help the clinician in those kind of diagnoses
(see Table 2).
TABLE 2. Personality Disorders. Guide to implementation.
 
A standard approach to the assessment of personality pathology using the DSM 5 model could be the 
following: 
 
1. Is impairment in personality functioning (self and interpersonal) present or not? 
2. If so, rate the level of impairment in self (identity or self-direction) and interpersonal 
(empathy or intimacy) functioning on the Levels of Personality Functioning Scale.  
3. Is one of the 6 defined types present?  
4. If so, record the type and the severity of impairment.  
5. If not, is PD-Trait Specified present?  
6. If so, record PDTS, identify and list the trait domain(s) that are applicable, and record the 
severity of impairment.  
7. If a PD is present and a detailed personality profile is desired and would be helpful in the 
case conceptualization, evaluate the trait facets.  
8. If neither a specific PD type nor PDTS is present, evaluate the trait domains and/or the trait 
facets, if these are relevant and helpful in the case conceptualization. 
I would like just mention that this approach has been considered «impossibly
complicated and cumbersome». «The DSM 5 dimensional proposals are especially
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problematic, ad hoc, unworkably complex, vague, untested, and premature. If anything,
the poorly executed introduction of unwieldy dimensions into DSM 5 is likely to give
them a bad name and poison the well for their future necessary acceptance. It is also
possible that the use of dimensions may create problematic unintended consequences
in insurance, disability, and forensic determinations» (Frances, 2009b, p. 391).
It is far beyond the scope of the present paper to review in detail all of the
proposals above mentioned. I will only focus and discuss one of the key pillars of
psychiatric classification: schizophrenia spectrum psychosis.
Psychosis
Although there is a growing consensus in thinking that schizophrenia is an obsolete
construct that needs to be superseded, the process of «deconstructing» psychosis (Van
Os and Tamminga, 2007) has not yet yielded any tangible results. Dimensional approaches
to schizophrenia and psychosis (Allardyce, Suppes, and Van Os, 2007) have not yet ripe
enough to displace the old Kraepelinian concept. So DSM 5 will seemingly retain the
main pillars that have stood up since the begining of the XX century.
A controversial but well founded innovation in the field is related to the prodromal
phases of psychosis. The evidence accumulated over the past 15 years that points to
the existence of attenuated symptoms long before the appearance of a clear-cut psychotic
episode has motivated the proposal for a Attenuated Psychosis Syndrome (APS) new
category (see Table 3). The validity of criteria for identifying at-risk individuals has been
published (Woods et al., 2009). The potential benefit of establishing a category «involves
the evidence that psychotic illness is most effectively treated early in the course raising
the potential that early intervention may have long lasting benefit that is not achievable
with later therapeutic intervention» (American Psychiatric Association, DSM-5
Development, 2010b).
TABLE 3. Attenuated Psychosis Syndrome. Criteria.
All six of the following: 
a) Characteristic symptoms: at least one of the following in attenuated form with intact reality 
testing, but of sufficient severity and/or frequency that it is not discounted or ignored. 
a. Delusions 
b. Hallucinations 
c. Disorganized speech  
b) Frequency/Currency: symptoms meeting criterion A must be present in the past month and 
occur at an average frequency of at least once per week in past month. 
c) Progression: symptoms meeting criterion A must have begun in or significantly worsened in 
the past year. 
d) Distress/Disability/Treatment Seeking:  symptoms meeting criterion A are sufficiently 
distressing and disabling to the patient and/or parent/guardian to lead them to seek help. 
e) Symtpoms meeting criterion A are not better explained by any DSM-5 diagnosis, including 
substance-related disorder. 
f) Clinical criteria for any DSM-V psychotic disorder have never been met. 
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A substantial body of prospective research has established that individuals who
develop attenuated psychotic symptoms accompanied by dysfunction at school and
similar problems at home are much more likely than individuals in the general population
to develop schizophrenia or other psychotic disorders within 2 years (at a rate of 10%-
30% compared with 0.02%) (Cannon et al., 2008). The research has been conducted at
multiple sites in the United States and Europe, and the convergence on a set of criteria
that can be diagnosed reliably by different observers and have the external validity of
leading to a dire illness has been established (Carpenter and Van Os, 2011).
Experts emphasize that current distress is a necessary criterion for this diagnosis.
These individuals already need help because of behavioral and cognitive problems at
school and at home. They need psychological help and, in some cases, medication,
which they cannot receive in most health care systems if they have not received a
commensurate diagnosis. Without a diagnosis, the consequence is that they cannot get
help in the stage of illness when it might be most helpful for the prevention of chronic
illness (Carpenter and Van Os, 2011). In a Norwegian study, for example, early recognition
of individuals with attenuated psychotic symptoms has resulted in an overall reduction
in suicide rate because individuals have initiated treatment before they reach their
sickest state (Melle et al., 2006). The APS advocates claim that even if they do not
convert to psychosis, the distress and dysfunction that these people experience are
severe enough to merit help.
On the opposite side of this debate, some leading figures claim the contrary, fear
a «public health catastrophe» and think that the whole idea is dangerously premature.
For example, Allan Frances states that «the APS is probably one of the most worrisome
of all the suggestions made for DSM 5. The false positive rate would be alarming-70%
to 75% in the most careful studies and likely to be much higher once the diagnosis is
official, in general use, and becomes a target for drug companies. Hundreds of thousands
of teenagers and young adults (especially, it turns out, those on Medicaid) would
receive the unnecessary prescription of atypical antipsychotic drugs. There is no proof
that the atypical antipsychotics prevent psychotic episodes, but they do most certainly
cause large and rapid weight gains (see the recent FDA warning) and are associated
with reduced life expectancy-to say nothing about their high cost, other side effects,
and stigma” (Frances, 2010).
And more…
It is not reassuring news that the two former heads of the DSM-III and DSM-IV
task forces, Robert Spitzer and Allen Frances, have seriously condemned some of the
DSM 5 proposals and methods. First, they have publicly criticized the APA for mandating
that DSM 5 task force members sign a nondisclosure agreement, effectively conducting
the whole process in secret. Although the APA has since instituted a disclosure policy
for DSM 5 task force members, many still believe the Association has not gone far
enough in its efforts to be transparent and to protect against industry influence. It has
been noted that «the fact that 70% of the task force members have reported direct
industry ties -an increase of almost 14% over the percentage of DSM-IV task force
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members who had industry ties- shows that disclosure policies alone, especially those
that rely on an honor system, are not enough and that more specific safeguards are
needed» (Cosgrove, Bursztajn, Kupfer and Regier, 2009, p. 1).
A general concern points to the potential increase of mental disorder rates. As
Allen Frances puts it: «These might come in two forms: a) new diagnoses that would
be extremely common in the general population (especially after marketing by an ever
alert pharmaceutical industry), and b) lowered diagnostic thresholds for many of the
existing disorders, from the elimination of the «clinical significance» DSM-IV criterium
DSM 5 would create tens of millions of newly misidentified false positive «patients»,
thus greatly exacerbating the problems caused already by an overly inclusive DSM-IV.
There would be massive overtreatment with medications that are unnecessary, expensive,
and often quite harmful. DSM 5 appears to be promoting what we have most feared—
the inclusion of many normal variants under the rubric of mental illness, with the result
that the core concept of «mental disorder» is greatly undermined» (Frances, 2010, p. 1).
New diagnoses are being proposed that seem problematic: First of all, the Attenuated
Psychosis Syndrome, already discussed. But also the Mixed Anxiety Depressive Disorder,
the Minor Neurocognitive Disorder, the Binge Eating Disorder, the Temper Dysfunctional
Disorder with Dysphoria, the Hypersexuality Disorder, the Behavioral Addictions category
and the Paraphilic Coercive Disorder, all of which share the presence of nonspecific
symptoms an blurred distictions with normal range behaviors and hence would most
probably increase the large mass of false positive cases. Moreover, this would provide
too good ammunition for a new antipsychiatry wave or, at least, for a reasonable
argument against medicalisation of different kinds of free-willy elected, or cultural
variants of normal behavior.
So long as psychiatric diagnosis is stuck in its current descriptive level, there is
little to be gained and much to be lost in frequently and arbitrarily changing the system.
Descriptive diagnosis should remain fairly stable until, disorder by disorder, we gradually
attain a more fundamental and explanatory understanding of causality (Frances, 2009a).
Beyond DSM 5: What to expect for the next DSM generation?
DSM diagnostic entities, based solely on clinical phenomena, continue to dominate
research in all its domains, despite a large and growing body of data, derived both from
clinical sources and from the laboratory, signaling profound problems in the way that
DSM-IV divides and classifies the complex world of psychopathology. The recent
advances in neuroscience, molecular biology, and brain imaging are not yet relevant to
the clinical purposes of everyday psychiatric diagnosis. «The clearest evidence supporting
this disappointing fact is that not even 1 biological test is ready for inclusion in the
criteria sets for DSM-5» (Frances, 2009a, p. 2).
The boundaries of these categories have not been predictive of treatment response.
And, perhaps most important, these categories, based upon presenting signs and
symptoms, may not capture fundamental underlying mechanisms of dysfunction. At
present, DSM-IV categories do not map well onto the genome, just as they fail to map
onto clinical populations (Bernstein, 2011). Psychiatry is still far away from the rest of
Int J Clin Health Psychol, Vol. 12. Nº 2
OBIOLS. DSM 5: Precedents, present and prospects 289
medical specialties, where the use of biological parameters for diagnostic purposes is
widespread.
¿Is this caused by a radically different nature of the object under study? Are
psychopathological entities not amenable to scientific investigation? I am sure they are.
It is just a matter of complexity and difficulty, hence of time. The question is: are we
ready for a radical change in our classification system? Or, as Frances signaled: «The
DSM 5 goal to effect a «paradigm shift» in psychiatric diagnosis is absurdly premature….
There can be no dramatic improvements in psychiatric diagnosis until we make a
fundamental leap in our understanding of what causes mental disorders» (Frances,
2009b, p. 392 ).
Should agencies be more flexible in the upcoming future to fund clinical research
that is not strictly based on DSM 5 criteria? Will scientific journal editors be willing to
accept papers on the biology of psychotic dimensions or symptoms rather than
«schizophrenia»? Hopefully, they will. Meanwhile, the NIMH is launching the Research
Domain Criteria (RDoC) project to create a framework for research on pathophysiology,
especially for genomics and neuroscience, which ultimately will inform future classification
schemes of mental disorders. The RDoC project is intended to be the next step in a long
journey, one that continues the process begun in the 1970s of ensuring diagnosis that
has both reliability and validity (Insel et al., 2010). It is expected that the RDoC can
contribute to a nosology in which disorders are grouped by underlying pathophysiological
similarities rather than phenomenological observations. Interestingly, the polemical proposal
discussed above for the «attenuated psychosis syndrome» diagnosis was developed
largely «because of the sizable body of literature on psychosis risk and vulnerability
factors detailing structural and functional imaging, neurocognition, and genetic outcomes»
(Kupfer and Regier, 2011). If this is true, it would mean that DSM 5.1 will require not
only lots of new neuroscientific evidence but also a great deal of mind shifting and
prejudice overcoming.
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